$DBVT News
Last published 2d ago
- 2d agoDBVTGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - DBV TECHNOLOGIES SAEarnings Call TranscriptsOkay, good morning, everyone. My name is Yatin Suneja, one of the biotech analysts here at Guggenheim. Welcome to our third annual Healthcare Innovation Conference. Our first presenting company is DBV. From the company,
- 1w agoDBVTDBV Technologies to Participate in Upcoming November Investor ConferencesGlobeNewswireChâtillon, France, November 2, 2026 DBV Technologies to Participate in Upcoming November Investor Conferences DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today
- 2w agoDBVTDBV Technologies S.A. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoDBVTDBV Technologies Q3 2026 Results and Business Update Conference Call - DBV TECHNOLOGIES SAEarnings Call TranscriptsWelcome to the DBV Technologies third quarter 2026 results and business update conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressin
- 2w agoDBVTDBV Technologies Reports Third Quarter 2026 Financial Results and Business UpdateGlobeNewswireChâtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children
- 2w agoDBVTDBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026GlobeNewswireChâtillon, France, October 27, 2026 DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 Company to host investor conference call and webcast at 5:00pm ET DBV
- 2mo agoDBVTDBV Technologies to Participate in Upcoming September Investor ConferencesGlobeNewswireChâtillon, France, September 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company, today
- 2mo agoDBVTInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026GlobeNewswireInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE
- 3mo agoDBVTDBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on NasdaqGlobeNewswireChâtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (TRQX:DBVp) (the "Company"), a
- 3mo agoDBVTDBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of SalesGlobeNewswireChâtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company,
- 3mo agoDBVTDBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the ReportGlobeNewswireChâtillon, France, July 16, 2026 DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical
- 3mo agoDBVTDBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business UpdateGlobeNewswireChâtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA for the VIASKIN®
- 4mo agoDBVTDBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026GlobeNewswireChâtillon, France, July 14, 2026 DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 Company to host investor conference call and webcast at 5:00 p.m. ET DBV
- 4mo agoDBVTHalf-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFGlobeNewswireAMF Regulated InformationChâtillon, France, July 6, 2026 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today issued
- 4mo agoDBVTDBV Update Conference Call - DBVEarnings Call TranscriptsGood day everyone and welcome to the DBV Business Update conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followe
- 4mo agoDBVTDBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for FilingGlobeNewswireChâtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in
- 4mo agoDBVTDBV Technologies Announces Inclusion in the Euronext Tech Leaders IndexGlobeNewswireChâtillon, France, June 23, 2026 DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced that the Company has
- 5mo agoDBVTDBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewswireChâtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical
- 5mo agoDBVTDBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026GlobeNewswireChâtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, VIASKIN®
- 5mo agoDBVTDBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewswireChâtillon, France, June 5, 2026 DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company,
- 5mo agoDBVTInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026GlobeNewswireInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE
- 5mo agoDBVTDBV Technologies Announces the Results of its 2026 Combined General MeetingGlobeNewswireChâtillon, France, June 3, 2026 DBV Technologies Announces the Results of its 2026 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (TRQX:DBVp), a late stage biopharmaceutical
- 5mo agoDBVTDBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut AllergyGlobeNewswireChâtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The study is
- 6mo agoDBVTCombined General Meeting of June 3, 2026GlobeNewswireChâtillon, France, May 13, 2026 Combined General Meeting of June 3, 2026 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (TRQX:DBVp), a late-stage
- 6mo agoDBVTDBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NasdaqGlobeNewswireChâtillon, France, May 12, 2026 DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical
- 6mo agoDBVTDBV Technologies Reports First Quarter 2026 Financial ResultsGlobeNewswireChâtillon, France, April 30, 2026 DBV Technologies Reports First Quarter 2026 Financial Results Reported cash and cash equivalents of $229 million as of March 31, 2026 —providing funding into the second quarter of
- 7mo agoDBVTInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026GlobeNewswireInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE
- 7mo agoDBVTDBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration DocumentGlobeNewswireChâtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company (the
- 7mo agoDBVTDBV Technologies Reports Full Year 2025 Financial Results and Business UpdateGlobeNewswireChâtillon, France, March 26, 2026 DBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic
- 7mo agoDBVTDBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual ReviewGlobeNewswireChâtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (TRQX:DBVp), a
- 8mo agoDBVTDBV Technologies to Participate in Upcoming March Investor ConferencesGlobeNewswireChâtillon, France, March 4, 2026 DBV Technologies to Participate in Upcoming March Investor Conferences DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced the company will participate
- 8mo agoDBVTInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026GlobeNewswireInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE
- 8mo agoDBVTDBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual MeetingGlobeNewswireChâtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN®
- 9mo agoDBVTDBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual MeetingGlobeNewswireChâtillon, France, February 10, 2026 DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment
- 9mo agoDBVTDBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech SummitGlobeNewswireChâtillon, France, February 9, 2025 DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit DBV Technologies (TRQX:DBVp) (the "Company"), a late-stage biopharmaceutical company,
- 9mo agoDBVTInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026GlobeNewswireInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE
- 9mo agoDBVTDBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 FinancingGlobeNewswireChâtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The Company is
- 10mo agoDBVTInformation Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025GlobeNewswireInformation Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Notice:This
- 10mo agoDBVTHalf-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFGlobeNewswireAMF Regulated InformationChâtillon, France, January 7, 2026 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today
- 10mo agoDBVTInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025GlobeNewswireInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE
- 11mo agoDBVTDBV UPDATE CONFERENCE CALL - DBVEarnings Call TranscriptsWelcome to the DBV Technologies Update Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After t
- 11mo agoDBVTDBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 YearsGlobeNewswireChâtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary
- 11mo agoDBVTInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025GlobeNewswireInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE
- 12mo agoDBVTDBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 YearsGlobeNewswireChâtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on
- 1y agoDBVTDBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation ConferenceGlobeNewswireChâtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today
- 1y agoDBVTDBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial OfficerGlobeNewswireChatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced the
- 1y agoDBVTInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025GlobeNewswireInformation Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE
- 1y agoDBVTDBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of DirectorsGlobeNewswireChâtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (TRQX:DBVp), (the "Company" or "DBV"), a clinical-stage biopharmaceutical
- 1y agoDBVTDBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific MeetingGlobeNewswireChâtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today announced upcoming
- 1y agoDBVTDBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on NasdaqGlobeNewswireChâtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (TRQX:DBVp) (the "Company"), a clinical-stage